Kangstem Biotech Co. Ltd - Asset Resilience Ratio

Latest as of June 2026: 38.73%

Kangstem Biotech Co. Ltd (217730) has an Asset Resilience Ratio of 38.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 217730 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩26.50 Billion

≈ $17.96 Million USD Cash + Short-term Investments

Total Assets

₩68.42 Billion

≈ $46.37 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Kangstem Biotech Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Kangstem Biotech Co. Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Kangstem Biotech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Kangstem Biotech Co. Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩26.50 Billion	38.73%
Total Liquid Assets	₩26.50 Billion	38.73%

Asset Resilience Insights

Very High Liquidity: Kangstem Biotech Co. Ltd maintains exceptional liquid asset reserves at 38.73% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Kangstem Biotech Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Kangstem Biotech Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Kangstem Biotech Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Kangstem Biotech Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	44.91%	₩36.60 Billion ≈ $24.80 Million	₩81.49 Billion ≈ $55.23 Million	+12.28pp
2024-12-31	32.63%	₩18.27 Billion ≈ $12.38 Million	₩55.99 Billion ≈ $37.94 Million	-13.35pp
2023-12-31	45.98%	₩37.36 Billion ≈ $25.32 Million	₩81.25 Billion ≈ $55.06 Million	+0.47pp
2022-12-31	45.51%	₩36.68 Billion ≈ $24.86 Million	₩80.59 Billion ≈ $54.62 Million	-9.33pp
2021-12-31	54.84%	₩56.57 Billion ≈ $38.34 Million	₩103.15 Billion ≈ $69.90 Million	+9.23pp
2020-12-31	45.61%	₩37.63 Billion ≈ $25.50 Million	₩82.51 Billion ≈ $55.91 Million	+32.88pp
2019-12-31	12.73%	₩14.47 Billion ≈ $9.81 Million	₩113.64 Billion ≈ $77.01 Million	-2.52pp
2018-12-31	15.25%	₩11.16 Billion ≈ $7.56 Million	₩73.19 Billion ≈ $49.60 Million	-8.51pp
2017-12-31	23.76%	₩10.91 Billion ≈ $7.39 Million	₩45.91 Billion ≈ $31.12 Million	-25.37pp
2016-12-31	49.13%	₩23.31 Billion ≈ $15.80 Million	₩47.44 Billion ≈ $32.15 Million	--

pp = percentage points

About Kangstem Biotech Co. Ltd

KQ:217730 Korea Biotechnology

Market Cap

$135.45 Million

₩199.87 Billion KRW

Market Cap Rank

#18131 Global

#793 in Korea

Share Price

₩2125.00

Change (1 day)

-0.70%

52-Week Range

₩1397.00 - ₩4615.00

All Time High

₩18836.30